Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

UFPT vs UTMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UTMD Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

UTMD Overall Winner 6-Pillar Tally: UFPT 1 – 4 UTMD (1 Tie) Matrix Metrics: UFPT 3 – 7 UTMD

As of Nov 16, 2026, Utah Medical Products Inc (UTMD) is the stronger overall head-to-head candidate over UFP Technologies Inc (UFPT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas UTMD carries 52.9/100 (HOLD) at $72.36 (13.0x Forward P/E, 34.3% operating margin).

  • Growth vs. Quality Trade-Off: UTMD earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. UFPT 42.6/100 HOLD) and 0.23β · 33% Vol risk profile, whereas UFPT leads top-line expansion (+11.6% YoY revenue growth, 3.80x PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile UTMD is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UFPT vs UTMD
UFPT NASDAQ
UFP Technologies Inc
Surgical & Medical Instruments & Apparatus
$298.54
-2.14% 1D
Market Cap $2.4B
TTM Revenue $650M
Forward P/E 24.7x
Beta / 30D Vol 1.64β · 77% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.1%) with fading momentum, RSI 50
RSI-14: 49.8 · SMA20: $298.97 · SMA50: $293.17
UTMD NASDAQ Head-to-Head Winner
Utah Medical Products Inc
Surgical & Medical Instruments & Apparatus
$72.36
+0.54% 1D
Market Cap $204.9M
TTM Revenue $35M
Forward P/E 13.0x
Beta / 30D Vol 0.23β · 33% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 46.0 Fund 49.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope 0.3%) with fading momentum, RSI 50
RSI-14: 49.9 · SMA20: $72.12 · SMA50: $73.04

6-Pillar Scorecard Institutional Category Breakdown (UFPT 1 – 4 UTMD)

Columns: Metric · UFPT · UTMD
1. Valuation Multiples UTMD
Forward P/E 24.7x 13.0x
Trailing P/E 31.2x 21.6x
PEG Ratio 3.80x 4.25x
EV / Revenue 3.6x 5.9x
2. Growth & Scale UFPT
Revenue Growth (YoY) +11.6% -12.1%
Earnings Growth (YoY) +25.1% +6.8%
TTM Revenue (USD) $650M $35M
Market Cap $2.4B $204.9M
3. Profitability & Quality UTMD
Gross Margin 28.9% 57.7%
Operating Margin 15.4% 34.3%
Net Profit Margin 11.8% 30.5%
Return on Equity (ROE) 17.2% 8.8%
4. Balance Sheet & Cash Flow UTMD
Cash Generation (TTM) $120M EBITDA $13M EBITDA
Cash Flow Margin 18.5% EBITDA Mgn 38.3% EBITDA Mgn
Net Cash / Leverage $62.70 Book/Sh · 17.2% ROE $38.83 Book/Sh · 8.8% ROE
Dividend Yield None (0.00%) 0.42%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 42.3% (3rd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Distribution
6. R&D & Supply-Chain Moat UTMD
OpEx & R&D Intensity 13.5% of Rev ($88M) 23.4% of Rev ($8.2M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat High-Margin Pricing Power Moat
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UFPT (3) vs UTMD (7)
Institutional Metric UFPT UTMD Criterion Row Edge
Market Capitalization
Scale
$2.4B $204.9M Larger Scale UFPT
Trailing P/E Ratio
Valuation
31.2x 21.6x Lower Multiple UTMD
Forward P/E Ratio
Valuation
24.7x 13.0x Lower Multiple UTMD
Revenue Growth (YoY)
Growth
+11.6% -12.1% Higher Growth UFPT
Operating Margin (TTM)
Profitability
15.4% 34.3% Higher Margin UTMD
Net Profit Margin
Profitability
11.8% 30.5% Higher Margin UTMD
Return on Equity (ROE)
Capital Efficiency
17.2% 8.8% Higher ROE UFPT
52-Week Range Position
Momentum
74% ($174–$342) 80% ($54–$77) Stronger Trend UTMD
Beta / 30D Volatility
Risk Regime
1.64β · 77% Vol 0.23β · 33% Vol Lower Realized Risk UTMD
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 52.9 / 100 (HOLD) Higher Composite UTMD
Trailing 12M Revenue (USD)
Operating Scale
$650M $35M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
28.9% 57.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.80x PEG · 3.6x EV/Rev 4.25x PEG · 5.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$120M EBITDA ($62.70 Book/Sh · 17.2% ROE) $13M EBITDA ($38.83 Book/Sh · 8.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon UFPT +5.25 pp
UFPT: +2.36% · UTMD: -2.89%
3M Horizon UTMD +5.42 pp
UFPT: -4.92% · UTMD: +0.5%
6M Horizon UFPT +24.38 pp
UFPT: +37.44% · UTMD: +13.06%
1Y Horizon UTMD +1.54 pp
UFPT: +27.42% · UTMD: +28.96%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UFPT vs UTMD. Trailing 12-month operating profitability (UFPT 15.4% vs UTMD 34.3%) and valuation multiples (UFPT 24.7x vs UTMD 13.0x Forward P/E) are benchmarked directly in Pillar 4 below.

UFPT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$650M
Gross Margin28.9%
Op. Margin15.4%
ROE / Fwd P/E17.2% · 24.7x
UTMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$35M
Gross Margin57.7%
Op. Margin34.3%
ROE / Fwd P/E8.8% · 13.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UFPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.3%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UFPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UTMD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UTMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UFPT Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $2.4B market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($88M)
90D Engineering Disclosures 0 Published
UTMD Moat Profile High-Margin Pricing Power Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $204.9M market capitalization and 34.3% operating margin.
OpEx & R&D Reinvestment 23.4% of Rev ($8.2M)
90D Engineering Disclosures 0 Published

Investor FAQ UFPT vs UTMD Key Questions & Quantitative Answers

As of Nov 16, 2026, Utah Medical Products Inc (UTMD) is the stronger overall head-to-head candidate over UFP Technologies Inc (UFPT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas UTMD carries 52.9/100 (HOLD) at $72.36 (13.0x Forward P/E, 34.3% operating margin). Growth vs. Quality Trade-Off: UTMD earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. UFPT 42.6/100 HOLD) and 0.23β · 33% Vol risk profile, whereas UFPT leads top-line expansion (+11.6% YoY revenue growth, 3.80x PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile UTMD is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

UFPT leads the Growth & Scale pillar: UFPT posts +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin), compared with UTMD at -12.1% YoY revenue growth and +6.8% YoY earnings growth on $35M TTM revenue (57.7% gross margin, 34.3% operating margin). On trailing 12-month operating scale, UFPT generates $650M in USD-normalized revenue versus $35M for UTMD. In operating R&D and SG&A reinvestment, UFPT deploys 13.5% of Rev ($88M) (0 90-day corporate R&D disclosures) versus 23.4% of Rev ($8.2M) (0 disclosures) for UTMD.

UTMD screens cheaper on headline valuation multiples. UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin), whereas UTMD trades at 13.0x Forward P/E, 21.6x Trailing P/E, 4.25x PEG, and 5.9x EV/Revenue (38.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UFPT (17.2% ROE) versus UTMD (8.8% ROE) capital efficiency.

In options market volatility and institutional positioning, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk). By comparison, UTMD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.23β · 33% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.